Skip to main content

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company developing novel ophthalmic therapeutics. The company commercializes Xdemvy (lotilaner ophthalmic solution), the first FDA-approved treatment for Demodex blepharitis, alongside advancing pipeline candidates for rosacea and Lyme disease. Main revenue drivers derive from commercial sales of Xdemvy to specialty pharmacies, pharmaceutical distributors, and eye care practices. Tarsus Pharmaceuticals serves optometrists, ophthalmologists, eye care clinics, and patients suffering from blepharitis across the United States. The company holds a pioneering market position as the sole provider of a targeted therapeutic for Demodex blepharitis. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc is listed on the Nasdaq Stock Market.

5 of the funds FundTelligence covers report a position in Tarsus Pharmaceuticals.

Legal name
Tarsus Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
5

Funds holding Tarsus Pharmaceuticals

Loading...